IASO Bio acquires Singapore’s MediSix Therapeutics to expand global cell therapy platform

The acquisition adds MediSix’s proprietary T-cell engineering technologies and pipeline to IASO Bio’s integrated cell therapy capabilities while strengthening its presence in Singapore and international markets.

IASO Bio has acquired Singapore-based MediSix Therapeutics, bringing the company’s proprietary immune-engineering technologies and cell therapy pipeline into its existing global cell therapy organisation.

The transaction expands IASO Bio beyond its established BCMA CAR-T franchise by adding technologies designed to address challenges in T-cell malignancies and other difficult-to-treat diseases, while establishing a stronger R&D presence in Singapore.

Field	Content
Alert Type	Deal
Companies	IASO Bio; MediSix Therapeutics
Deal Type	Acquisition
Asset or Company	MediSix Therapeutics and its proprietary T-cell engineering technology and cell therapy pipeline
Therapy Area(s)	Haematological malignancies; Oncology; Autoimmune diseases
Technology or Modality	CAR-T cell therapy; T-cell engineering; Protein Expression BLocker (PEBL) technology
Deal Value	Financial terms of the acquisition have not been disclosed.
Development Stage	Research and clinical-stage cell therapy programmes
Geography	Singapore; China; United States; global
What Happened	IASO Bio has acquired MediSix Therapeutics, a Singapore-headquartered biotechnology company developing engineered T-cell therapies for cancer and autoimmune diseases. The acquisition brings MediSix’s proprietary technologies, intellectual property and development pipeline into IASO Bio’s existing cell therapy organisation. MediSix was founded in 2016 by Professor Dario Campana, whose research contributed to the development of the CAR construct used in the first FDA-approved CAR-T therapy, and has developed technologies including Protein Expression BLocker (PEBL) to address challenges associated with engineering CAR-T cells against T-cell malignancies. Financial terms were not disclosed. (Medisixtx)
Why It Matters	IASO Bio already has integrated discovery, development, manufacturing and commercial capabilities in cell therapy, anchored by its approved BCMA CAR-T therapy equecabtagene autoleucel. Acquiring MediSix adds a complementary T-cell engineering platform and programmes targeting areas beyond IASO’s established multiple myeloma franchise, while giving the company an R&D base within Singapore’s biotechnology ecosystem. (IASO Bio)
Supporting Context	MediSix’s PEBL technology is designed to suppress selected proteins inside engineered T cells, an approach intended to overcome challenges encountered when developing CAR-T therapies against targets also expressed by normal T cells. Its pipeline has included PCART7, a CD7-directed programme investigated for T-cell malignancies. (Medisixtx)
Strategic Rationale	IASO Bio gains proprietary cell-engineering technologies, additional pipeline assets and an established Singapore operation that complements its existing presence in China and the US. The acquisition follows IASO’s broader international expansion, including the June 2026 Singapore approval of equecabtagene autoleucel, its first marketing authorisation for the therapy outside Greater China. (IASO Bio)
Potential Impact	Integrating MediSix’s technologies could broaden the range of cell therapy targets and diseases addressed by IASO Bio and support development of future programmes for T-cell malignancies and other indications. The eventual impact will depend on the development progress and clinical performance of the acquired programmes.
Key Takeaway	The MediSix acquisition adds specialist T-cell engineering technology and a Singapore R&D presence to IASO Bio as it builds a broader international cell therapy platform.
What to Watch	Integration of MediSix’s Singapore operations and technology platform into IASO Bio, development priorities for the acquired pipeline and whether MediSix’s technologies generate new clinical programmes within IASO’s expanded portfolio.
Primary Source	IASO Bio / MediSix Therapeutics acquisition announcement
Relevant Date	18 August 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector 

• Contact us on: support@nuaxia.com